The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02796183|
Recruitment Status : Completed
First Posted : June 10, 2016
Last Update Posted : June 10, 2016
Ondokuz Mayıs University
Information provided by (Responsible Party):
Volkan YETER, Neon Hospital
This study evaluates the effects of subconjunctivally injected bevacizumab in patients with diffuse diabetic macular edema.
|Condition or disease||Intervention/treatment||Phase|
|Diabetic Macular Edema||Drug: Subconjunctival bevacizumab (Altuzan)||Not Applicable|
At baseline, the macular thicknesses of both eyes of the patients with persistant diabetic macular edema were measured by optical coherence tomography. After 3.75mg bevacizumab was injected into subconjunctival space of the eyes with diabetic macular edema. The measurements of the macular thicknesses were repeated by optical coherence tomography in 15th, 30th, 60th day after injections. The macular thickness measurements before and after injection were compared.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema|
|Study Start Date :||January 2015|
|Actual Primary Completion Date :||April 2016|
|Actual Study Completion Date :||May 2016|
Diabetic macular edema
Bevacizumab (Altuzan) was injected subconjunctival space of the patients.
Drug: Subconjunctival bevacizumab (Altuzan)
Subconjunctival injections of Altuzan 3.75mg were applied in order to eliminate the macular edema.
Primary Outcome Measures :
- Central Macular Thickness [ Time Frame: one year (between May 2015 and May 2016) ]
No Contacts or Locations Provided